Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5153 maintenance for acute myeloid leukemia in first complete remission
ACTRN12621000246886Phase 2Not yet recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in acute myeloid leukemia (AML) comparing AZD5153 with Standard of care observation (2 arms). Primary endpoint: Failure-free survival. Planned start Apr 2021; status: not yet recruiting.
02
Drugs
AZD5153
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ACTRN12621000246886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000246886.